Kura Oncology (KURA) Other financing activities (2017 - 2026)
Kura Oncology (KURA) posted quarterly Other financing activities of $69000.0 for Q1 2026, down 51.75% year-over-year from $143000.0 in Q1 2025, and down 93.92% quarter-over-quarter from $1.1 million in Q4 2025.
Kura Oncology (KURA) Other financing activities (2017 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Other financing activities for 10 consecutive years, with $69000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities fell 51.75% year-over-year to $69000.0; the TTM figure through Mar 2026 stood at $1.7 million (down 72.24% YoY), while the FY2025 annual figure was $1.8 million, down 79.16% from the prior year.
- Other financing activities slipped to $69000.0 in Q1 2026 per KURA's latest filing, from $1.1 million in the prior quarter.
- Across five years, Other financing activities topped out at $3.0 million in Q2 2024 and bottomed at $69000.0 in Q1 2026.
- Historically, Other financing activities has averaged $1.1 million across 5 years, with a median of $749000.0 in 2023.
- Annual changes were most pronounced in 2024 — Other financing activities jumped 2521.43% — and 2025, when it tumbled 94.4%.
- Kura Oncology's Other financing activities stood at $567000.0 in 2022, then gained by 21.87% to $691000.0 in 2023, then grew by 16.79% to $807000.0 in 2024, then jumped by 40.64% to $1.1 million in 2025, then tumbled by 93.92% to $69000.0 in 2026.
- Business Quant data shows KURA's Other financing activities at $69000.0 in Q1 2026, $1.1 million in Q4 2025, and $515000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.50 Mn |
| Jun 30, 2026 | 1.50 Mn |
| Mar 31, 2026 | 69,000.00 |
| Mar 31, 2026 | 69,000.00 |
| Dec 31, 2025 | 1.14 Mn |
| Dec 31, 2025 | 1.14 Mn |
| Jun 30, 2025 | 515,000.00 |
| Jun 30, 2025 | 515,000.00 |
| Mar 31, 2025 | 143,000.00 |
| Mar 31, 2025 | 143,000.00 |
| Dec 31, 2024 | 807,000.00 |
| Dec 31, 2024 | 807,000.00 |
| Sep 30, 2024 | 2.20 Mn |
| Sep 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 3.04 Mn |
| Jun 30, 2024 | 3.04 Mn |
| Mar 31, 2024 | 2.56 Mn |
| Mar 31, 2024 | 2.56 Mn |
| Dec 31, 2023 | 691,000.00 |
| Dec 31, 2023 | 691,000.00 |